Formulary Group work programme


Forthcoming submissions 2015

This list is indicative and may be subject to change.

Adalimumab - SMC 1068/15 - Formulary Group advice will be published by 4th August 2015. (Indication: treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies).

Adapalene/benzoyl peroxide (Epiduo®) - SMC 682/11 - Formulary Group advice will be published by 4th August 2015. (Indication: cutaneous treatment of acne vulgaris when comedones, papules and pustules are present).

Ampremilast - SMC 1052/15 - in progress. (Indication: for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA)).

Ampremilast - SMC 1053/15 - in progress. (Indication: alone or in combination with disease modifying anti-rheumatic drugs (DMARDs), for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy).

Apixaban - SMC 1029/15 - Formulary Group advice will be published by 4th August 2015. (Indication: treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE in adults).

Ceftobiprole - SMC 943/14 - in progress. (Indication: treatment of the following infections in adults: hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP); community-acquired pneumonia (CAP)).

Cetuximab - SMC 1012/14 - in progress.  (Indication: treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer).

Clindamycin/tretinoin (Treclin®) - SMC 1010/15Formulary Group advice will be published by 4th August 2015. (Indication: for the topical treatment of acne vulgaris when comedones, papules and pustules are present in patients 12 years or older).

Darunavir - SMC 1069/15 - Formulary Group advice will be published by 4th August 2015. (Indication: in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in paediatric patients aged 3 to 12 years and ≥15kg).

Fluoxetine - FGA005/15 - Formulary Group advice will be published by 4th August 2015. (Indication: depressive episodes, obsessive-compulsive disorder, bulimia nervosa).

Fostair® NEXThaler® - FGA004/15 - Formulary Group advice will be published by 4th August 2015. (Indication: for adult patients for the regular treatment of asthma). 

Magnesium aspartate dihydrate - SMC 1042/15 - in progress. (Indication: for the treatment and prevention of magnesium deficiency, as diagnosed by a doctor).

Moviprep - FG1388/15 - in progress. (Indication: bowel cleansing preparation).

Nintedanib - SMC 1027/15 - in progress. (Indication: in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy). 

Posaconazole - SMC 1067/15 - Formulary Group advice will be published by 4th August 2015. (Indication:  for use in the treatment of fungal infections in adults).

Riociguat - SMC 1056/15 - Formulary Group advice will be published by 4th August 2015. (Indication: Pulmonary arterial hypertension (PAH)).

Secukinumab - SMC 1054/15 - Formulary Group advice will be published by 4th August 2015. (Indication: treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy).

Sorafenib - SMC 1055/15 - Formulary Group advice will be published by 4th August 2015. (Indication: treatment of patients with progressive, locally advanced or metastatic, differentiated thyroid carcinoma, refractory to radioactive iodine).

Tinzaparin - SMC 1061/15 - Formulary Group advice will be published by 4th August 2015. (Indication: patients with solid tumours: extended treatment of symptomatic venous thrombo-embolism (VTE) and prevention of its recurrence).

Vedolizumab - SMC 1064/15 - Formulary Group advice will be published by 4th August 2015. (Indication: for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist).

Publication schedule

This web page is updated monthly, within 7 working days of publication of SMC advice.

END

« Previous: Formulary Group | Top | Next: Formulary Group decisions index »